Dapsone - USA

IPR decision: May 29, 2020

AIA Review #	Filing Date	Institution Decision Date	Petitioner	Patent	Respondent	Status
IPR2019-00207	11/06/2018	05/10/2019	Amneal	9,517,219	Almirall LLC	All Challenged Claims Unpatentable
IPR2019-01095	06/07/2019	11/27/2019	Mylan	9,517,219	Almirall LLC	All Challenged Claims Unpatentable

US 9,517,219 (Allergan, Inc.; Exp: 11/18/2033)

1. A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the topical pharmaceutical composition does not comprise adapalene.

6. A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w diethylene glycol monoethyl ether; about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the topical pharmaceutical composition does not comprise adapalene.